text_1: Cancers that initially benefit from epidermal growth factor receptor targeted therapies later become refractory through several mechanisms.
text_2: All patients with metastatic lung, colorectal, pancreatic or head and neck cancers who initially benefit from epidermal growth factor receptor (EGFR)-targeted therapies eventually develop resistance.